Enantiomerically pure phosphoindoles as HIV inhibitors
3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.
1. A pure compound of the following formula, or a pharmaceutically acceptable salt thereof:
2. A pure compound of the following formula, or a pharmaceutically acceptable salt thereof:
3. The compound of claim 1 that is enantiomerically pure.
4. The compound of claim 1 that is substantially free of its opposite enantiomer.
5. The compound of claim 1 that comprises at least 80%, 90%, 95%, or 99% by weight of the designated enantiomer.
6. A pharmaceutically acceptable salt of the compound of claim 1 .
7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier, excipient or diluent, wherein said composition is substantially free of the opposite enantiomer of said compound.
8. The pharmaceutical composition of claim 7 , which is in a pharmaceutically acceptable oral dosage form.
9. The pharmaceutical composition of claim 8 , wherein the oral dosage form is a capsule or tablet.
10. The pharmaceutical composition of claim 8 wherein the compound is enantiomerically pure.
11. A pharmaceutical composition comprising a compound of claim 1 and a second anti-HIV agent, wherein said composition is substantially free of the opposite enantiomer of said compound.
12. The pharmaceutical composition of claim 11 wherein the second anti-HIV agent is a protease inhibitor or an integrase inhibitor.
13. The pharmaceutical composition of claim 11 wherein the second anti-HIV agent is amprenavir, tipranavir, indinavir, saquinavir, lopinavir, ritronavir, fosamprenavir, darunavir, atazanavir, nelfinavir, brecanivir, GS-8374, Elvitegravir, GSK-364735, or raltegravir.
14. A method of treating an HIV infection comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .
15. The method of claim 14 , wherein the compound is in a pharmaceutically acceptable oral dosage form.
16. The method of claim 15 , wherein the oral dosage form is a capsule or tablet.
17. The method of claim 14 , wherein the compound is enantiomerically pure.
18. The method of claim 14 , wherein the compound is administered orally.
19. The method of claim 18 , wherein the compound is administered orally once per day.
20. A method of inhibiting HIV replication comprising the step of contacting a cell infected with HIV with a compound of claim 1 .
21. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier, excipient or diluent, wherein said composition comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% , or 99% by weight of the designated enantiomer, wherein the remaining weight percentage is made up by the pharmaceutical carrier, excipient or diluent, and wherein the weight is based upon the total weight of the composition.
22. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical carrier, excipient or diluent, wherein said composition comprises at least about 80%, 90%, 95%, or 99% by weight of the designated enantiomer, and wherein the weight is based upon the total weight of the compound.
23. The compound of claim 2 that is enantiomerically pure.
24. The compound of claim 2 that is substantially free of its opposite enantiomer.
25. The compound of claim 2 that comprises at least 80%, 90%, 95%, or 99% by weight of the designated enantiomer.
26. A pharmaceutically acceptable salt of the compound of claim 2 .
27. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutical carrier, excipient or diluent, wherein said composition is substantially free of the opposite enantiomer of said compound.
28. The pharmaceutical composition of claim 27 , which is in a pharmaceutically acceptable oral dosage form.
29. The pharmaceutical composition of claim 28 , wherein the oral dosage form is a capsule or tablet.
30. The pharmaceutical composition of claim 28 wherein the compound is enantiomerically pure.
31. A pharmaceutical composition comprising a compound of claim 2 and a second anti-HIV agent, wherein said composition is substantially free of the opposite enantiomer of said compound.
32. The pharmaceutical composition of claim 31 wherein the second anti-HIV agent is a protease inhibitor or an integrase inhibitor.
33. The pharmaceutical composition of claim 31 wherein the second anti-HIV agent is amprenavir, tipranavir, indinavir, saquinavir, lopinavir, ritronavir, fosamprenavir, darunavir, atazanavir, nelfinavir, brecanivir, GS-8374, Elvitegravir, GSK-364735, or raltegravir.
34. A method of treating an HIV infection comprising administering to a subject in need thereof an effective amount of a compound of claim 2 .
35. The method of claim 34 , wherein the compound is in a pharmaceutically acceptable oral dosage form.
36. The method of claim 35 , wherein the oral dosage form is a capsule or tablet.
37. The method of claim 34 , wherein the compound is enantiomerically pure.
38. The method of claim 34 , wherein the compound is administered orally.
39. The method of claim 38 , wherein the compound is administered orally once per day.
40. A method of inhibiting HIV replication comprising the step of contacting a cell infected with HIV with a compound of claim 2 .
41. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutical carrier, excipient or diluent, wherein said composition comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 99% by weight of the designated enantiomer, wherein the remaining weight percentage is made up by the pharmaceutical carrier, excipient or diluent, and wherein the weight is based upon the total weight of the composition.
42. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutical carrier, excipient or diluent, wherein said composition comprises at least about 80%, 90%, 95%, or 99% by weight of the designated enantiomer, and wherein the weight is based upon the total weight of the compound.